Update on rufinamide in childhood epilepsy
Giangennaro CoppolaClinic of Child and Adolescent Neuropsychiatry, Medical School, University of Salerno, ItalyAbstract: Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1)methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anti...
Guardado en:
Autor principal: | Coppola G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e856e9be879d4a43bc052b883c77d175 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
por: Carl E Stafstrom
Publicado: (2009) -
Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
por: Jessica Gresham, et al.
Publicado: (2010) -
Update on treatment of partial onset epilepsy: role of eslicarbazepine
por: Markus Rauchenzauner, et al.
Publicado: (2010) -
Profile of lacosamide and its role in the long-term treatment of epilepsy: a perspective from the updated NICE guideline
por: Delgado Nunes V, et al.
Publicado: (2013) -
Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review
por: Balagura G, et al.
Publicado: (2020)